Capmatinib dihydrochloride
CAS: 1197376-85-4
Ref. 3D-XXB37685
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued |
Product Information
Capmatinib dihydrochloride is a molecule with antiproliferative, anti-angiogenic and cell death properties. It inhibits the c-met receptor tyrosine kinase, which is involved in tumor growth and angiogenesis. Capmatinib dihydrochloride has been shown to be effective against various cancers including breast cancer, non-small cell lung cancer, and prostate cancer. It also has an affinity for the antibody that targets the c-met receptor tyrosine kinase. This drug also has a patent and is one of the first in a new class of oncology drugs known as selpercatinibs. Capmatinib dihydrochloride can be used as a treatment for cancers that are resistant to other therapies or when other treatments have not worked.